Ascendancy of semi-synthetic biomaterials from design towards democratization
Source abstract
Abstract
Semi-synthetic goldilocks material design integrates the tunable characteristics of synthetic materials and the refined complexity of natural components, enabling for the progress of biomaterials across length scales. Accelerated translational success may thus be possible for more personalized and accessible products.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. Cao, L. et al. Nature 605, 551–560 (2022).10.1038/s41586-022-04654-9 ↗
2. Gillmore, J. D. et al. N. Engl. J. Med. 385, 493–502 (2021).10.1056/NEJMoa2107454 ↗
3. Kellner, M. J. et al. Nat. Protoc. 14, 2986–3012 (2019).10.1038/s41596-019-0210-2 ↗
4. Broughton, J. P. et al. Nat. Biotechnol. 38, 870–874 (2020).10.1038/s41587-020-0513-4 ↗
5. Broto, M. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-022-01179-0 (2022).10.1038/s41565-022-01179-0 ↗
6. Scully, M. et al. N. Engl. J. Med. 380, 335–346 (2019).10.1056/NEJMoa1806311 ↗
7. Loynachan, C. N. et al. ACS Nano 12, 279–288 (2018).10.1021/acsnano.7b06229 ↗
8. Akinc, A. et al. Nat. Biotechnol. 26, 561–569 (2008).10.1038/nbt1402 ↗
9. Adams, D. et al. N. Engl. J. Med. 379, 11–21 (2018).10.1056/NEJMoa1716153 ↗
10. Corbett, K. S. et al. Nature 586, 567–571 (2020).10.1038/s41586-020-2622-0 ↗
11. Cheng, Q. et al. Nat. Nantechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
12. Rurik, J. G. et al. Science 375, 91–96 (2022).10.1126/science.abm0594 ↗
13. Kis, Z. et al. Vaccines 9, 3 (2021).10.3390/vaccines9010003 ↗
14. Serov, N. & Vinogradov, V. Adv. Drug Deliv. Rev. 184, 114194 (2022).10.1016/j.addr.2022.114194 ↗
15. Atala, A. et al. Lancet 367, 1241–1246 (2006).10.1016/S0140-6736(06)68438-9 ↗
16. Place, E. S., Evans, N. D. & Stevens, M. M. Nat. Mater. 8, 457–470 (2009).10.1038/nmat2441 ↗
17. Du, Y. et al. Proc. Natl Acad. Sci. USA 105, 9522–9527 (2008).10.1073/pnas.0801866105 ↗
18. Lancaster, M. A. et al. Nature 501, 373–379 (2013).10.1038/nature12517 ↗
19. Huh, D. et al. Science 328, 1662–1668 (2010).10.1126/science.1188302 ↗
20. Ingber, D. E. Nat. Rev. Genet. 23, 467–491 (2022).10.1038/s41576-022-00466-9 ↗
21. Drug Trials Snapshots Summary Report: Five-Year Summary and Analysis of Clinical Trial Participation and Demographics Contents (FDA, 2015).
22. Mak, W. W. S. et al. Adm. Policy Ment. Health 34, 497–503 (2007).10.1007/s10488-007-0133-z ↗
23. Ball, P. Nature 589, 16–18 (2021).10.1038/d41586-020-03626-1 ↗
24. Gupta, R. Nat. Biotechnol. 39, 664–666 (2021).10.1038/s41587-021-00942-3 ↗
25. Salamanca-Buentello, F. & Daar, A. S. Nat. Nanotechnol. 16, 358–361 (2021).10.1038/s41565-021-00899-z ↗
26. Wood, C. S. et al. Nature 566, 467–474 (2019).10.1038/s41586-019-0956-2 ↗
27. Hajipour, M. J. et al. Nat. Commun. 12, 2984 (2021).10.1038/s41467-021-23230-9 ↗
28. Mortazavi, A. et al. Nat. Methods 5, 621–628 (2008).10.1038/nmeth.1226 ↗
29. Tang, F. et al. Nat. Methods 6, 377–382 (2009).10.1038/nmeth.1315 ↗
30. Stål, P. L. et al. Science 353, 78–82 (2016).10.1126/science.aaf2403 ↗
31. Hao, Y. et al. Cell 184, 3573–3587 (2021).10.1016/j.cell.2021.04.048 ↗